Adagio Medical Announces First Patient Enrollment in its iCLAS™ U.S. IDE Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Persistent Atrial Fibrillation

LAGUNA HILLS, Calif., Dec. 16, 2019 /PRNewswire/ -- Adagio Medical, Inc. (Adagio) today announced it has enrolled the first patient in its iCLAS™ Investigational Device Exemption (IDE) trial. The FDA approved study aims to evaluate the safety and efficacy of Adagio's ultra-low temperature...

from PR Newswire: https://ift.tt/2PMYbGE